Delving into the Latest Updates on Shugan Granules with Synapse

Overview

Basic Info

Drug Type

Herbal medicine

Synonyms-

Target-

Mechanism-

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication

Flank PainBreast hyperplasia

Inactive Indication-

Originator Organization

Kunming Chinese Medicine Factory Co. Ltd.

Active Organization

Kunming Chinese Medicine Factory Co. Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

CN (02 Jun 2020),

Flank Pain

Regulation-

Login to view timeline

On the basis of the Phase II clinical trial, a low-dose of Shugan Granule was used as the test group, and compared with placebo and positive drugs in parallel to further verify the clinical efficacy and safety of Shugan Granule in the treatment of liver depression and qi stagnation syndrome in fibrocystic fibrosis.

Start Date29 Jun 2015

Sponsor / Collaborator

Kunming Chinese Medicine Factory Co. Ltd.

CTR20131224 / CompletedPhase 2

舒肝颗粒治疗乳腺增生病（肝郁气滞证）随机、双盲、剂量反应对照、多中心临床研究

[Translation] A randomized, double-blind, dose-response controlled, multicenter clinical study on Shugan granules in the treatment of breast hyperplasia (liver depression and qi stagnation syndrome)

采用随机、双盲、剂量反应安慰剂平行对照、多中心临床试验，评价舒肝颗粒治疗乳腺增生病（肝郁气滞证）的有效性及安全性。

[Translation]

A randomized, double-blind, dose-response, placebo-controlled, multicenter clinical trial was conducted to evaluate the efficacy and safety of Shugan Granule in the treatment of hyperplasia of the breast (liver depression and qi stagnation syndrome).

Start Date27 Jun 2011

Sponsor / Collaborator

Kunming Chinese Medicine Factory Co. Ltd.

100 Clinical Results associated with Shugan Granules

Login to view more data

100 Translational Medicine associated with Shugan Granules

Login to view more data

100 Patents (Medical) associated with Shugan Granules

Login to view more data

11

Literatures (Medical) associated with Shugan Granules

01 Mar 2024·Heliyon

Study on the mechanism of Shugan Lidan Xiaoshi granule in preventing acute pancreatitis based on network pharmacology and molecular docking

Article

Author: Chen, Zitong ; Liu, Bin ; Wang, Yang ; Wang, Wujie ; Li, Yuliang ; Wang, Jiaxing

Background:

Shugan Lidan Xiaoshi granules (SLXG) is a herbal granule formulation developed by extensively modifying multiple traditional Chinese medicine compound prescriptions known for their ability to dissolve stones. It is primarily used for the prevention and treatment of cholelithiasis and possesses significant therapeutic potential in both preventing and treating acute pancreatitis. However, the preventive effects of SLXG on cholelithiasis-related complications, such as acute pancreatitis (AP), have been inadequately researched.

Methods:

TCMSP database was searched to identify the active components and targets of SLXG's action. The disease gene databases (GeneCards, OMMI, PharmGKB, DrugBank) were used to retrieve the targets associated with AP. A TCM ingredient target network was then constructed by using the intersection of these two datasets. The overlapping targets underwent network analyses, including Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG)and Protein-Protein Interaction (PPI) analyses. Molecular docking was performed to examine the interaction patterns between the active ingredients and central targets.

Results:

A "Traditional Chinese Medicine-Component-Target" complex network consisting of 10 traditional Chinese medicines, 114 compounds, and 164 targets was constructed. GO and KEGG analysis showed that SLXG has the potential to regulate the response of oxygen-containing compounds, apoptosis, and inflammatory factors. Nine central genes were identified by the PPI network and subnetwork. IL6 was chosen as the most significant gene for molecular docking. The three active compounds of SLXG: quercetin, luteolin, and paeoniflorin, along with the active site of IL6 have a good binding ability and thus play a preventive role in AP.

Conclusion:

This study provides evidence of the effective preventive role of SLXG against AP, as indicated by bioinformatics analysis. The preventive effect of SLXG is attributed to its multi-component, multi-target, and multi-pathway mechanisms. This finding provides a solid foundation for future research on the clinical application and mechanism of action of drugs.

01 Jan 2024·Journal of ethnopharmacology

Corrigendum to “Clinical efficacy of Shugan granule in the treatment of mixed anxiety-depressive disorder: A multicenter, randomized, double-blind, placebo-controlled trial” [J. Ethnopharmacol. 290 (2022) 115032]

Author: He, Huiling ; Zhao, Huixin ; Guo, Rongjuan ; Temu, Qile ; Shang, Jinlin ; Yang, Dongdong ; Li, Zengxiang ; An, Jinlan ; Wang, Xinping ; Yu, Hua ; Chen, Xiaochun ; Zhang, Yurong ; Qi, Lihong ; Zou, Ting ; Lin, Jiaming ; Li, Yang ; Wang, Qiufeng ; Li, Liqi ; Cai, Xiaojun ; Li, Anhong ; Wang, Baoshen ; Zhang, Yuan

01 Jan 2024·Phytomedicine : international journal of phytotherapy and phytopharmacology

Analysis of bioactive components and synergistic action mechanism of ShuGan-QieZhi Capsule for treating non-alcoholic fatty liver disease

Article

Author: Huang, Xiaohui ; Yao, Huijuan ; Zhu, Hongyan ; Zhang, Yufeng ; Qi, Jia ; Zhu, Tong ; Chen, Jihui ; Hua, Haibing ; Zhang, Jian

BACKGROUND:

ShuGan-QieZhi capsule (SGQZC) is a traditional Chinese preparation used to treat hyperlipidemia and obesity, even non-alcoholic fatty liver disease (NAFLD). However, its therapeutic effects, main bioactive ingredients, as well as potential mechanisms for NAFLD are still unclear.

PURPOSE:

To investigate the pharmacological effect, main active ingredients, and mechanisms of SGQZC against high-fat diet (HFD)-induced NAFLD in mice.

METHODS:

NAFLD models were established by feeding C57BL/6 J mice an HFD for 24 weeks. From the 12th week, HFD-fed mice received daily gavage of either SGQZC or silibinin for 12 weeks. Hepatic hypertrophy parameters, along with hepatic and systemic lipid metabolism changes in NAFLD mice, were assessed. Oil red O and histopathological staining techniques determined lipid accumulation and liver injury severity. qRT-PCR analysis measured the expression of genes tied to liver lipid metabolism and inflammation. HPLC-MS/MS identified the primary components of SGQZC in the serum. Human normal hepatocytes (LO2) and hepatic stellate cells (LX-2) were used to screen SGQZC's bioactive ingredients. Network pharmacological analysis, transcriptomics, and western blotting delved into SGQZC's synergistic mechanisms against NAFLD.

RESULTS:

SGQZC ameliorated abnormal lipid metabolism and liver hypertrophy in mice with HFD-induced NAFLD, consequently reducing hepatic lipid accumulation, inflammatory cell infiltration, and liver impairment. Eight crucial components of SGQZC were detected in serum using HPLC-MS/MS and were found to effectively attenuate lipid accumulation and inflammation in liver cells. Further investigation indicated that SGQZC modulates MAPK pathway and AKT/NF-κB pathway, subsequently improving lipid metabolism and inflammation.

CONCLUSION:

SGQZC alleviates NAFLD by synergistically modulating the MAPK-mediated lipid metabolism and inhibiting AKT/NF-κB pathways-mediated inflammation. Our findings reveal the enormous potential of SGQZC for the treatment of NAFLD, providing a possible new clinical therapeutic strategy.

100 Deals associated with Shugan Granules

Login to view more data